Last update 28 Jun 2025

Amilomotide

Overview

Basic Info

Drug Type
Virus-like particle vaccine, Synthetic peptide vaccine, Therapeutic vaccine
Synonyms
Alzheimer's disease virus-like particle-based vaccine, Alzheimer's disease VLP-based vaccine, Beta-amyloid protein immunotherapy
+ [2]
Target
Action
inhibitors, stimulants
Mechanism
APP inhibitors(Beta amyloid A4 protein inhibitors), Immunostimulants
Active Indication-
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseDiscontinuedPhase 2/3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alzheimer DiseasePhase 3
United States
30 Nov 2015
Alzheimer DiseasePhase 3
Australia
30 Nov 2015
Alzheimer DiseasePhase 3
Belgium
30 Nov 2015
Alzheimer DiseasePhase 3
Canada
30 Nov 2015
Alzheimer DiseasePhase 3
Finland
30 Nov 2015
Alzheimer DiseasePhase 3
Germany
30 Nov 2015
Alzheimer DiseasePhase 3
Netherlands
30 Nov 2015
Alzheimer DiseasePhase 3
Spain
30 Nov 2015
Alzheimer DiseasePhase 3
Switzerland
30 Nov 2015
Alzheimer DiseasePhase 3
United Kingdom
30 Nov 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
APOE4 homozygotes
65
yrftjprhpp(aitdljpgnq) = kbyhmnkrlp mwjapfoipm (kyeifjnqec )
Positive
31 Dec 2021
Placebo
yrftjprhpp(aitdljpgnq) = avyxubnidh mwjapfoipm (kyeifjnqec )
Phase 2
121
jdtweiipgh(oyxretdipl) = twigautdpe ezuwjdtxmr (xykmrrqbhm, 16.7 - 33.8)
Positive
23 Dec 2016
Placebo
jdtweiipgh(oyxretdipl) = jfgaayfkuh ezuwjdtxmr (xykmrrqbhm, 0.2 - 31.9)
Not Applicable
-
vjxlmkhxoc(myxzjeisyy) = AEs occurred in 74.5% of CAD106-treated patients versus 63.6% of placebo-treated patients (core), and 82.2% experienced AEs during extension studies. Most AEs were mild to moderate in severity, were not study medication-related and did not require discontinuation. SAEs occurred in 19.1% of CAD106-treated patients and 36.4% of placebo-treated patients (core). One patient (CAD106-treated; 2201) reported a possibly study drug-related SAE of intracerebral hemorrhage. Four patients met criteria for amyloid-related imaging abnormalities (ARIA) corresponding to microhemorrhages: one was CAD106-treated (2201), one placebo-treated (2202) and two open-label CAD106-treated. No ARIA corresponded to vasogenic edema. Two patients discontinued extension studies because of SAEs (rectal neoplasm and rapid AD progression, respectively). cehcyrvnef (dymjpnenjr )
-
01 Jan 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free